Literature DB >> 15837408

Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography.

Nadir Ghanem1, Carsten Altehoefer, Stefan Högerle, Egbert Nitzsche, Christian Lohrmann, Oliver Schäfer, Elmar Kotter, Mathias Langer.   

Abstract

PURPOSE: We evaluated the diagnostic accuracy of magnetic resonance imaging (MRI) and positron emission tomography (PET) for detection of liver metastases in malignant melanoma.
MATERIAL AND METHODS: Thirty-five patients with 39 combined unenhanced MRI and fluorine-18 deoxyglucose (F-18 FDG) PET scans were prospectively studied. In discordant imaging findings final diagnosis was proven by clinical follow-up >6 months and demonstration of progressive liver metastases by at least one imaging method. Sensitivities and specificities were compared and the influence of lesion size and melanin content on diagnostic accuracy was determined.
RESULTS: MRI and PET were concordantly negative for presence and number of liver metastases in 28 patients and positive in four patients. PET and MRI were false positive in one patient each. In one patient MRI showed a single metastases not seen by PET and in one patient MRI demonstrated more metastases at the first examination. In follow-up investigations MRI revealed more metastases than PET in both patients. The sensitivities for lesion detection were 47% (16/34) for PET and 100% for MRI. Lesion detectability by PET was related to lesion size (P < 0.0001) but not to melanin content.
CONCLUSION: MRI is more sensitive in the detection of liver metastases in patients with malignant melanoma. Small lesions are easily missed by PET, while melanin content does not influence detectability by PET.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837408     DOI: 10.1016/j.ejrad.2004.07.005

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.

Authors:  Maryline Gardette; Claire Viallard; Salomé Paillas; Jean-Luc Guerquin-Kern; Janine Papon; Nicole Moins; Pierre Labarre; Nicolas Desbois; Pascal Wong-Wah-Chung; Sabine Palle; Ting-Di Wu; Jean-Pierre Pouget; Elisabeth Miot-Noirault; Jean-Michel Chezal; Francoise Degoul
Journal:  Invest New Drugs       Date:  2014-04-02       Impact factor: 3.850

Review 2.  CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.

Authors:  Maxime Barat; Sarah Guegan-Bart; Anne-Ségolène Cottereau; Enora Guillo; Christine Hoeffel; Maximilien Barret; Sébastien Gaujoux; Anthony Dohan; Philippe Soyer
Journal:  Abdom Radiol (NY)       Date:  2020-11-02

Review 3.  MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.

Authors:  Hui Shi; Zhen Cheng
Journal:  Acta Pharmacol Sin       Date:  2022-08-25       Impact factor: 7.169

4.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

5.  Sinonasal malignant melanoma with diffuse carcinomatosis: initial PET/CT staging and follow-up CT/MR imaging.

Authors:  Ba D Nguyen
Journal:  Radiol Case Rep       Date:  2015-11-06

6.  Targeted radiotherapy of pigmented melanoma with 131I-5-IPN.

Authors:  Xiaodong Xu; Lujie Yuan; Yongkang Gai; Qingyao Liu; Lianglan Yin; Yaqun Jiang; Yichun Wang; Yongxue Zhang; Xiaoli Lan
Journal:  J Exp Clin Cancer Res       Date:  2018-12-11

Review 7.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.